GlassScriptPhysician profile
Amy Lynn Wnek
NPI 1871547463
$1,373.24
in general payments reported to CMS, 2019-2025
13 companies · $475 in 2025
The $475 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $14.54 · 2021: $99.98 · 2022: $60.24 · 2023: $193 · 2024: $409 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,077.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,077.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $360.12 | 2024 | Ilet Bionic Pancreas |
| Tandem Diabetes Care, INC. | $230.10 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $217.54 | 2023-2025 | Minimed 780g |
| Abbott Laboratories | $125.50 | 2019-2021 | |
| Lilly USA, LLC | $114.51 | 2019-2022 | |
| Sequel Med Tech, LLC | $108.26 | 2025 | Twiist |
| Novo Nordisk INC | $88.35 | 2023-2025 | Wegovy |
| Ascendis Pharma Endocrinology INC | $28.90 | 2025 | Yorvipath |
| Insulet Corporation | $24.52 | 2019 | |
| Dexcom, INC. | $22.44 | 2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $21.74 | 2023 | |
| Janssen Pharmaceuticals, INC | $19.35 | 2019 | |
| Horizon Therapeutics Plc | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Wnek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.